Abbvie to present detailed results from phase iii studies in patients with chronic hepatitis C at the 2014 International Liver Congress™

AbbVie (NYSE: ABBV) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress™ (ILC) in London, April 9-13. Detailed results from the SAPPHIRE-I, SAPPHIRE-II, PEARL-III, and TURQUOISE-II studies will be presented at the ILC on April 10-12.

In presentations at the ILC, investigators will share detailed data results of four studies from AbbVie’s phase III clinical trial program, the largest phase III program of an investigational, all-oral, interferon-free regimen for the treatment of chronic hepatitis C virus (HCV) infection in genotype 1 (GT1) adult patients.

Following is a list of AbbVie’s phase III clinical trial program data being presented at the ILC:

• SAPPHIRE-II: Phase III Placebo-Controlled Study of an Investigational Interferon-Free, 12-Week Regimen in 394 Treatment-Experienced Adults with HCV GT1
  Oral Presentation: General Session 1 and Opening
  April 10, 14:00-14:15 BST; ICC Auditorium
• SAPPHIRE-I: Phase III Placebo-Controlled Study of an Investigational Interferon-Free, 12-Week Regimen in 631 Treatment-Naive Adults with HCV GT1
  Oral Presentation: General Session 2 and Awards 1
  April 11, 10:15-10:30 BST; ICC Auditorium
• PEARL-III: Sustained Virologic Response 12 Weeks Post-treatment (SVR12) with an Investigational 12-Week Regimen in 419 Treatment-Naive HCV GT1b-Infected Adults
  Late Breaker Poster: Poster P1299
  April 12, 9:00-18:00 BST; Poster Exhibition
• TURQUOISE-II: SVR12 Rates in 380 HCV GT1-Infected Adults with Compensated Cirrhosis Treated with an Investigational Regimen
  Oral Presentation: Late Breakers
  April 12, 15:30-15:45 BST; ICC Auditorium

AbbVie will present additional data in presentations throughout the Congress. The full ILC 2014 scientific program can be found at www.ilc-congress.eu/.